COPD: 기관지 확장제와 코르티코스테로이드를 사용한 관리

COPD management relies on several medication classes. Bronchodilators like ipratropium bromide and albuterol relax airway muscles and improve lung function. Inhaled corticosteroids enhance quality of life, though they don't halt lung function decline. Theophylline benefits patients who retain CO2 by improving ventilatory capacity. Antibiotics treat exacerbations caused by bacterial infections, while long-term oxygen therapy extends life expectancy in severe cases.

Bronchodilators reduce respiratory symptoms by relaxing muscles around the airways in the lungs. Ipratropium bromide, an anticholinergic agent, and albuterol, a β2-adrenergic agonist, are primary bronchodilators used in COPD treatment. These medications improve lung function and are administered through inhalers or nebulizers. Longer-acting forms require less frequent dosing, improving patient compliance and symptom control.

Systemically active glucocorticoids have demonstrated limited efficacy in treating COPD, whereas inhaled corticosteroids can improve patients' quality of life. However, neither approach halts the decline in lung function characteristic of COPD. Inhaled delivery targets airways directly while minimizing systemic side effects, making it the preferred corticosteroid route for COPD management.

Theophylline is particularly beneficial for COPD patients who retain CO2. It relaxes and opens airways while improving ventilatory capacity by enhancing diaphragm contractile function. However, its use is limited by narrow therapeutic margins and potential side effects including nausea, insomnia, and arrhythmias. Careful monitoring is necessary to maintain therapeutic effectiveness while minimizing adverse effects.

Antibiotics are essential for treating COPD exacerbations caused by lower airway bacterial infections. They reduce both the duration and severity of acute episodes, helping patients recover more quickly. Bacterial infections trigger inflammatory responses that worsen airway obstruction and respiratory symptoms, making antibiotic intervention a critical component of acute COPD management.

Long-term oxygen therapy (LTOT) is recommended for patients with severe COPD and chronic hypoxemia. LTOT reduces breathlessness and fatigue, improves sleep and mood, increases mobility, and can extend life expectancy in some cases. By maintaining adequate oxygen levels, LTOT helps prevent complications associated with chronic low blood oxygen and enhances overall quality of life.

Smoking is a significant risk factor for developing and exacerbating COPD, making cessation vital for disease management. Lifestyle modifications, particularly smoking cessation and avoiding smoke exposure, are essential components of COPD treatment alongside medication. Combined with regular physical activity, balanced diet, and avoidance of respiratory irritants, smoking cessation contributes substantially to better disease control and improved quality of life.